| Publications |
| |
|
Peer Review
All the articles listed here were peer reviewed before they were published. Peer review is the process
of subjecting an author's research to the scrutiny of others who are experts in the
same field. It is difficult for authors and researchers, whether individually or in
a team, to spot every mistake or flaw in a complicated piece of work. This is not necessarily
a reflection on those concerned, but because with a new and perhaps eclectic subject, an
opportunity for improvement may be more obvious to someone with special expertise or who
simply looks at it with a fresh eye. Therefore, showing work to others increases the
probability that weaknesses will be identified and improved. For both grant-funding and
publication in a scholarly journal, it is also normally a requirement that the subject
is both novel and substantial. Peer review is generally considered essential to academic
quality.
Impact Fator
The Impact factor was devised by Eugene Garfield, the founder of the
Institute for Scientific Information, now part of Thomson, a large worldwide
US-based publisher. Impact factors are calculated each year by the Institute for
Scientific Information for those journals which it indexes, and the factors and
indices are published in Journal Citation Reports.
Though the impact factor was originally intended as an objective measure of the
reputability of a journal (Garfield), it is now being increasingly applied to
measure the productivity of scientists. The way it is customarily used is to
examine the impact factors of the journals in which the scientist's articles
have been published. This has obvious appeal for an academic administrator who
knows neither the subject nor the journals.
|
 |
Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients.
Horlings HM, Lai C, Nuyten DS, Halfwerk H, Kristel P, van Beers E, Joosse SA, Klijn C, Nederlof PM, Reinders MJ, Wessels LF, van de Vijver MJ.
Clinical Cancer Research | 2010 Jan 12 | 16(2): 651-63
|
 |
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A
Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P, Nederlof P, Yu Q, Jonkers J, van Lohuizen M, Pietersen AM.
Breast Cancer Research | 2009 Aug 26 | 11(4):R63
|
 |
Deletion of Exons 1a-2 of BRCA1: A Rather Frequent Pathogenic Abnormality.
van den Ouweland AM, Dinjens WN, Dorssers LC, van Veghel-Plandsoen MM, Brüggenwirth HT, Withagen-Hermans CJ, Collée JM, Joosse SA, Terlouw-Kromosoeto JN, Nederlof PM.
Genetic Testing and Molecular Biomarkers | 2009 Apr 30 | 13(3): 399-406
|
 |
Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer.
Koski TA, Lehtonen HJ, Jee KJ, Ninomiya S, Joosse SA, Vahteristo P, Kiuru M, Karhu A, Sammalkorpi H, Vanharanta S, Lehtonen R, Edgren H, Nederlof PM, Hietala M, Aittomäki K, Herva R, Knuutila S, Aaltonen LA, Launonen V.
Genes, Chromosomes, and Cancer | 2009 Apr 16 | 48:544–551
|
 |
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J.
Cancer Research | 2009 Apr 15 | 69(8):3625-33
|
 |
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N, Ligtenberg MJ, Wessels LF, Axwijk P, Verhoef S, Hogervorst FB, Nederlof PM.
Breast Cancer Research and Treatment | 2008 Aug 14 | 116(3):479-89
|
 |
ESR1 gene amplification in breast cancer: a common phenomenon?
Horlings HM, Bergamaschi A, Nordgard SH, Kim YH, Han W, Noh DY, Salari K, Joosse SA, Reyal F, Lingjaerde OC, Kristensen VN, Børresen-Dale AL, Pollack J, van de Vijver MJ.
Nature Genetics | 2008 Jul | 40(7):807-8
|
 |
Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach.
Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, van Beers EH, Joosse SA, Wong N, Novak D, Quenneville LA, Grist SA; kConFab, Nederlof PM, Goldgar DE, Tavtigian SV, Monteiro AN, Ladias JA, Foulkes WD.
European Journal of Human Genetics | 2008 Jul | 16(7):820-32
|
 |
Automated array-CGH optimized for archival formalin-fixed, paraffin-embedded tumor material.
Joosse SA, van Beers EH, Nederlof PM.
BMC Cancer | 2007 Mar 7 | 7:43
|
 |
A multiplex PCR predictor for aCGH success of FFPE samples.
van Beers EH, Joosse SA, Ligtenberg MJ, Fles R, Hogervorst FB, Verhoef S, Nederlof PM.
British Journal of Cancer | 2006 Jan 30 | 94(2):333-7
|
| Also contributed to and acknowledged in |
 |
SIRAC: Supervised Identification of Regions of Aberration in aCGH datasets.
Lai C, Horlings HM, van de Vijver MJ, van Beers EH, Nederlof PM, Wessels LF, Reinders MJ.
BMC Bioinformatics | 2007 Oct 30 | 8:422
|
 |
Analysis of PALB2/FANCN-associated breast cancer families.
Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, Li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, Ashworth A, Tonin PN, Narod SA, Livingston DM, Foulkes WD.
Proceedings of the National Academy of Sciences of the United States of America (PNAS) | 2007 Apr 17 | 104(16):6788-93
|
 |
Reactive oxygen species play no role in the candidacidal activity of the salivary antimicrobial peptide histatin 5.
Veerman EC, Nazmi K, Van't Hof W, Bolscher JG, Den Hertog AL, Nieuw Amerongen AV.
Biochemical Journal | 2004 Jul 15 | 381(Pt 2):447-52
|
|
